Notice of Change to Key Dates for PAR-21-157 “The Midlife in the United States Study - Cognitive and Neurocognitive Precursors of AD/ADRD (U01 Clinical Trial Not Allowed)”
Notice Number:
NOT-AG-21-025

Key Dates

Release Date:

June 16, 2021

Related Announcements

PAR-21-157 - The Midlife in the United States Study - Cognitive and Neurocognitive Precursors of AD/ADRD (U01 Clinical Trial Not Allowed)

Issued by

National Institute on Aging (NIA)

Purpose

This notice informs potential applicants of changes to the Key Dates for Funding Opportunity Announcement (FOA) PAR-21-157 “The Midlife in the United States Study - Cognitive and Neurocognitive Precursors of AD/ADRD (U01 Clinical Trial Not Allowed). NIA is adding a receipt date of August 16, 2021 and changing the November 18, 2021 receipt date to February 1, 2022.

The following Section of PAR-21-157 has been modified:

Part 1. Overview Information

Key Dates

Currently Reads:

Letter of Intent Due Date(s): March 26, 2021

Application Due Dates: April 26, 2021, November 18, 2021

Scientific Merit Review: July 2021, March 2022

Advisory Council Review: August 2021, May 2022

Earliest Start Date: September 2021, July 2022

Expiration Date: November 19, 2021

Modified to Read (changes shown in bold italics):

Letter of Intent Due Date(s): March 26, 2021; July 16, 2021; and January 1, 2022

Application Due Dates: April 26, 2021; August 16, 2021; and February 1, 2022

Scientific Merit Review: July 2021, October 2021; and July 2022

Advisory Council Review: August 2021, January 2022, August 2022

Earliest Start Date: September 2021, April 2022, September 2022

Expiration Date: February 2, 2022

All other aspects of this FOA remain unchanged.

Inquiries

Please direct all inquiries to:

Dana Jeffrey Plude, Ph.D.
National Institute on Aging (NIA)
Telephone: 301-496-3136
Email: dana.plude@nih.gov


Weekly TOC for this Announcement
NIH Funding Opportunities and Notices